Skip to content

How the HPG axis works: The brain-testes connection explained

Vladimir Kotlov, MD avatar
Vladimir Kotlov, MD: Founder & CEO at Veedma
Oct 09, 2026 · 16 min read

Listen to this article as a podcast episode

May 21, 2026 · 19:29

The hypothalamic pituitary gonadal axis is a three step signaling chain: pulsatile GnRH from the hypothalamus triggers pituitary LH and FSH, and LH then drives Leydig cells in the testes to make testosterone. This “brain to testes” pathway also explains why low testosterone is not one disease, but a set of different failure points with different treatments. Once you understand testosterone negative feedback, the logic behind morning testing, LH and FSH measurement, and fertility preserving treatment becomes much clearer.

Find the cause before treating it

Choose a lab panel and get a clinical review with clear next steps.

Order your lab panel

Key takeaways

  • The HPG axis controls testosterone through a fixed sequence: hypothalamic GnRH, pituitary LH and FSH release, then testicular testosterone and sperm production.[1] [2]
  • High LH plus low testosterone points to primary hypogonadism, while low or inappropriately normal LH plus low testosterone points to secondary hypogonadism.[3] [4]
  • Testosterone should be measured on a fasting morning sample and confirmed with a repeat test, because levels peak early in the day and vary within the same man.[3] [5]
  • When total testosterone is near the lower limit of normal or a condition alters SHBG, the Endocrine Society recommends measuring free testosterone by equilibrium dialysis or estimating it with an accurate formula.[3]
  • In phase III trials in men with secondary hypogonadism, testosterone gel lowered LH, FSH, and sperm counts, while Enclomiphene raised testosterone, LH, and FSH and kept sperm counts in the normal range.[6]
  • The Endocrine Society guideline suggests pituitary MRI in men with secondary hypogonadism when prolactin stays elevated, when headache or visual symptoms suggest a mass, when other pituitary hormones are deficient, or when testosterone is below 150 ng/dL.[3]

What the HPG axis does

The hypothalamic pituitary gonadal (HPG) axis is the hormone signaling chain that links the brain and the testes and controls how testosterone and sperm are produced. The hypothalamus is the brain region that initiates reproductive hormone signaling. The pituitary is the small gland beneath the brain that relays that signal into the bloodstream. The testes are the organs that make testosterone and sperm.

GnRH starts the signal

GnRH, short for gonadotropin releasing hormone, is released by the hypothalamus in pulses rather than as a constant stream, and pituitary gonadotroph cells respond to that rhythm by releasing LH and FSH. According to a 2015 European consensus statement on congenital hypogonadotropic hypogonadism, GnRH is the master hormone regulating the reproductive axis, and deficient production, secretion, or action of GnRH leads to absent puberty and infertility.[1] If the GnRH signal is weak, irregular, or suppressed, the rest of the axis falls with it.

This is why male hypogonadism can start above the testes, even when the testes themselves can still respond.

LH, FSH, and testicular function

LH and FSH have different jobs inside the testes, and together they coordinate testosterone and sperm production.[2]

LH, or luteinizing hormone, stimulates Leydig cells, the testosterone producing cells in the testes. Inside these cells, cholesterol is converted through a sequence of steroidogenic enzymes into testosterone.

FSH, or follicle stimulating hormone, acts mainly on Sertoli cells, the support cells that nurture developing sperm. FSH does not make most testosterone directly, but it regulates the proliferation and maturation of germ cells, both on its own and together with LH.[2] A 2021 review in the International Journal of Molecular Sciences also described a man whose LH mutation cut testosterone production to 1% to 2% of normal, yet whose few mature Leydig cells still supported complete spermatogenesis, a finding that questions how much intratesticular testosterone sperm production actually requires.[2]

This is why LH, FSH, and testosterone should always be interpreted together. A man can have low testosterone because the testes are failing, because the pituitary is under signaling, or because both problems coexist.

How negative feedback controls testosterone

Negative feedback keeps the HPG axis in balance. When testosterone rises, some of it is converted to estradiol by the aromatase enzyme, and both hormones signal the hypothalamus and pituitary that enough sex steroid is present. GnRH pulses slow, and LH and FSH release falls.

The same mechanism explains why exogenous testosterone suppresses the body’s own production. When outside testosterone raises circulating androgen levels, the brain turns down the upstream signal, largely through estradiol mediated feedback. LH falls, FSH falls, intratesticular testosterone falls, and sperm production declines. In two randomized phase III trials published in 2016 in BJU International, overweight men with secondary hypogonadism who used testosterone gel for 16 weeks had lower LH and FSH and a marked reduction in sperm production.[6]

According to the 2018 Endocrine Society guideline, testosterone therapy should not be started in men who are planning fertility in the near term.[3]

Why Enclomiphene works differently

Enclomiphene raises testosterone by blocking estrogen feedback at the hypothalamus rather than by replacing testosterone from outside the body.

Enclomiphene is the purified trans isomer, separated from the estrogenic cis isomer zuclomiphene. By blocking estrogen receptors at the hypothalamus, it prevents the brain from registering the estradiol feedback signal. GnRH output rises, pituitary LH and FSH rise, and the testes produce more testosterone through the body’s own pathway.

The downstream effect differs from testosterone therapy. In the same 2016 phase III trials, Enclomiphene raised testosterone, LH, and FSH and kept sperm concentration in the normal range, while testosterone gel raised testosterone but lowered LH, FSH, and sperm counts.[6] Because the axis stays active, testicular function is expected to be maintained.

FeatureExogenous testosteroneEnclomiphene
Effect on GnRHSuppresses it through negative feedbackIncreases it by blocking estrogen feedback
Effect on LH and FSHUsually lowers bothUsually raises or maintains both
Effect on testicular testosterone productionSuppresses endogenous productionStimulates endogenous production
Effect on spermatogenesisCan suppress itPreserved it in phase III trials
Best fitPrimary hypogonadism, or secondary disease that does not respond to stimulationSecondary or functional hypogonadism with an intact axis

Why LH and FSH are essential

LH and FSH show whether low testosterone comes from testicular failure or failed brain signaling, which is why guidelines treat them as essential tests.[3] [4]

A low testosterone value alone does not tell you where the defect is. According to the AUA guideline, clinicians should measure serum LH in men with low testosterone, and the result directs further evaluation.[4]

High LH plus low testosterone indicates primary hypogonadism: the brain is signaling hard, but the testes cannot respond. Low or inappropriately normal LH plus low testosterone indicates secondary hypogonadism. In that pattern, the testes may still be capable of working, but the hypothalamus or pituitary is not sending enough signal.

That distinction determines treatment. In primary hypogonadism, increasing pituitary signaling will not restore testosterone because the testes are not responding adequately. Secondary and functional hypogonadism often can respond to stimulation therapy, especially when the axis is suppressed rather than structurally destroyed. For a deeper diagnostic framework, see Primary vs secondary hypogonadism.

Why free testosterone still matters

Free testosterone is the small fraction of testosterone in the blood that is not bound to proteins.

Most laboratories still lean heavily on total testosterone, which can miss men whose free testosterone is low despite a “normal” total value. According to the 2018 Endocrine Society guideline, men whose total testosterone is near the lower limit of normal, or who have a condition that alters SHBG, should have free testosterone measured by equilibrium dialysis or estimated with an accurate formula.[3] A 2019 review in Maturitas added that most free testosterone assays are unreliable, that most immunoassays lose accuracy at the low end of the normal male range, and that mass spectrometry is the gold standard for measuring testosterone.[5]

If you want a fuller explanation of why one lab number can be misleading, see Why your testosterone test came back “normal” and why that might be wrong.

How estradiol, SHBG, and prolactin shape the axis

Estradiol, SHBG, and prolactin each alter HPG axis behavior in ways that can change both diagnosis and treatment selection.

Estradiol and obesity driven suppression

In men, estradiol is produced by aromatization of testosterone, much of it in adipose tissue.

Estradiol provides part of the negative feedback that slows GnRH and LH release. In obesity, aromatase activity rises, more testosterone is converted to estradiol, and the hypothalamus receives a stronger feedback signal. LH output falls, and testosterone production falls with it. This is one proposed mechanism behind obesity related functional hypogonadism, alongside insulin resistance and inflammation, and it helps explain why functional suppression is common in real world practice.

If the axis is intact but suppressed, lifestyle changes and stimulation therapy can make sense before lifelong replacement. For a broader discussion of reversibility, see Functional vs organic hypogonadism.

SHBG and the gap between total and free testosterone

SHBG, or sex hormone binding globulin, is a protein made in the liver that binds testosterone tightly and reduces the free fraction available to tissues.

The 2010 Endocrine Society guideline lists conditions that raise SHBG, including aging, liver cirrhosis, hyperthyroidism, anticonvulsant use, estrogen use, and HIV infection, and conditions that lower it, including moderate obesity, hypothyroidism, nephrotic syndrome, and glucocorticoid, progestin, or androgen use.[7] Two men with the same total testosterone can therefore have very different free testosterone levels.

Equilibrium dialysis measures free testosterone directly, while calculated free testosterone estimates it from total testosterone, SHBG, and albumin.

Prolactin as a central brake

Elevated prolactin is among the most common causes of hypogonadotropic, or secondary, hypogonadism, and it is often treatable.[8]

The Endocrine Society hyperprolactinemia guideline addresses prolactinomas and drug induced hyperprolactinemia as major causes of prolactin excess.[9] Antipsychotics and metoclopramide are classic medication examples. In men, high prolactin reduces GnRH secretion, lowers LH and FSH, and causes low testosterone. A 2023 review in the Journal of Clinical Endocrinology and Metabolism notes that larger prolactinomas are more common in men, describes dopamine agonists, mainly cabergoline, as the treatment of choice, and reports that they can restore fertility.[8] In that case the treatment target is the prolactin disorder itself rather than immediate hormone replacement.

Why timing and pituitary evaluation matter

Testosterone testing is most informative when it is done fasting in the morning and interpreted alongside pituitary warning signs.[3] [5]

Testosterone secretion follows a circadian rhythm, a repeating 24 hour biological cycle. A 2003 study in Clinical Endocrinology by Diver and colleagues, which sampled blood every 30 minutes for 24 hours in young and middle-aged men, found that total, free, and bioavailable testosterone peaked between 07:00 and 07:30 in both groups, and concluded that the daily rhythm is maintained in fit, healthy men into the seventh decade of life.[10] That is why blood is drawn in the morning, commonly between 07:00 and 11:00. The 2018 Endocrine Society guideline also recommends a fasting sample, because food intake can lower measured testosterone, and confirmation with a repeat morning measurement.[3]

Testosterone also varies within the same man from day to day. The 2019 Maturitas review lists circadian rhythm, day to day variability, and transient stressors as factors that affect measurement, and recommends a fasting morning sample that is repeated if the level is low.[5] One random afternoon draw is a weak basis for diagnosis.

The pituitary is the critical checkpoint

The pituitary is the relay station that converts the GnRH signal into LH and FSH, so damage there can silence the entire axis.

According to the Endocrine Society guideline and the EAU guideline, pituitary imaging becomes important when secondary hypogonadism comes with elevated prolactin, headache, visual disturbance, or other pituitary hormone deficiencies.[3] [11] The Endocrine Society also suggests imaging when testosterone is severely low, below 150 ng/dL.[3] Pituitary tumors, traumatic brain injury, and infiltrative diseases can all interfere with this checkpoint.

A low testosterone result plus low LH should therefore never be treated as a simple “just take testosterone” scenario. It may represent functional suppression, or a pituitary disorder that needs targeted investigation.

What causes low testosterone with low LH?

Low testosterone with low LH means the testes are not being told to work, so the search moves up the axis to the pituitary gland and hypothalamus.[4] In that pattern, the AUA guideline recommends measuring prolactin, because a prolactin secreting pituitary tumor (prolactinoma) suppresses LH.[4]

The same guideline lists pituitary causes of this pattern, including prolactinoma, pituitary radiation, pituitary surgery, iron overload from hemochromatosis, and other lesions near the pituitary.[4] It also links chronic opioid use to low testosterone.[4] Some men are born with the problem. In congenital hypogonadotropic hypogonadism, GnRH from the hypothalamus is missing or ineffective, so LH and FSH stay low, and when a reduced sense of smell comes with it, the condition is called Kallmann syndrome.[1]

The opposite pattern points elsewhere. When the testes themselves fail, as in Klinefelter syndrome, the pituitary pushes LH and FSH up. That is why total testosterone alone cannot tell these conditions apart, and why a confirmed low result deserves LH, FSH, and prolactin before any treatment decision.

How the axis guides treatment

The right treatment for low testosterone depends on whether the HPG axis is intact but suppressed, whether the testes are damaged, or whether pituitary signaling is organically impaired.

Functional secondary hypogonadism is the most common real world pattern. The axis is present but under signaling, often because obesity, metabolic disease, medications, or elevated estradiol are strengthening negative feedback. Weight loss and treating these conditions can raise testosterone, though the gain is usually modest. Stimulating the body’s own production is another option in this setting: in the 2016 phase III trials in overweight men with secondary hypogonadism, Enclomiphene raised testosterone while keeping sperm counts in the normal range.[6] Because Enclomiphene works with the existing axis, it may be possible to stop it if the suppressing factors improve.

Primary hypogonadism is different. If LH is high and testosterone is low, the testes are already receiving the message and cannot respond adequately, so Enclomiphene cannot help. Testosterone therapy is the standard hormonal treatment here, and the 2018 Endocrine Society guideline recommends it for men with symptomatic testosterone deficiency after a discussion of benefits, risks, and monitoring.[3]

Organic secondary hypogonadism creates a third pathway. If pituitary output is damaged, gonadotropin therapy with hCG and, when fertility is the goal, FSH can bypass the pituitary and stimulate the testes directly.[1] [11] For men whose pituitary still works and who do not need immediate fertility treatment, Enclomiphene is an oral alternative to hCG.

Axis patternTypical labsWhat it meansTreatment logic
Primary hypogonadismLow testosterone, high LH, often high FSHTestes are failing despite strong brain signalingTestosterone therapy is the standard hormonal treatment
Secondary hypogonadismLow testosterone, low or normal LH and FSHBrain signaling is inadequate, testes may still workStimulation therapy such as Enclomiphene may be considered if the axis is intact
Organic pituitary diseaseLow testosterone, low gonadotropins, often other pituitary cluesPituitary checkpoint is damagedInvestigate the lesion, then consider hCG and FSH if appropriate

Myth vs fact

Myth: LH and FSH are optional if testosterone is already low

Fact: LH and FSH are required to classify primary vs secondary hypogonadism, and that classification determines whether stimulation therapy is possible or futile.[3] [4]

Myth: TRT and Enclomiphene work the same way

Fact: TRT supplies testosterone from outside the body, while Enclomiphene blocks estrogen feedback at the hypothalamus so the body makes more of its own. In phase III trials, testosterone gel raised testosterone but lowered LH, FSH, and sperm counts, while Enclomiphene raised testosterone, LH, and FSH and kept sperm counts in the normal range.[6]

Myth: Obesity only affects testosterone by lowering self esteem

Fact: Excess adipose tissue lowers testosterone through physical mechanisms. Higher aromatase activity raises estradiol, which strengthens negative feedback on the hypothalamus and lowers LH, and insulin resistance and inflammation also contribute.

Myth: An afternoon testosterone test is good enough

Fact: Testosterone follows a morning dominant circadian rhythm and also varies within the same man over time, which is why guidelines recommend fasting morning testing, repeated if low.[3] [5]

Bottom line

The HPG axis works through a clear chain: GnRH from the hypothalamus stimulates pituitary LH and FSH, LH drives Leydig cell testosterone production, FSH supports Sertoli cell sperm production, and testosterone and estradiol feed back to slow the system when enough hormone is present. That loop is why LH and FSH are indispensable in diagnosis, why obesity can suppress testosterone, and why Enclomiphene can raise the body’s own testosterone in men with secondary or functional hypogonadism and an intact axis, while testosterone therapy suppresses it. For the full diagnostic and treatment roadmap, see the Low Testosterone hub.

Veedma offers testing that includes total and free testosterone measured by LC-MS/MS with LH and FSH, or a review of labs you already have, with care from licensed providers. When appropriate, treatment is Enclomiphene or the Enclomiphene plus tadalafil tablet. Enclomiphene is not an FDA-approved drug; it is prescribed after a provider confirms the diagnosis and is compounded by a licensed U.S. pharmacy.

References

  1. Boehm U, Bouloux PM, Dattani MT, et al. Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism–pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2015;11:547-64. PMID: 26194704
  2. Oduwole OO, Huhtaniemi IT, Misrahi M. The Roles of Luteinizing Hormone, Follicle-Stimulating Hormone and Testosterone in Spermatogenesis and Folliculogenesis Revisited. Int J Mol Sci. 2021;22. PMID: 34884539
  3. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103:1715-1744. PMID: 29562364
  4. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200:423-432. PMID: 29601923
  5. Kanakis GA, Tsametis CP, Goulis DG. Measuring testosterone in women and men. Maturitas. 2019;125:41-44. PMID: 31133215
  6. Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117:677-85. PMID: 26496621
  7. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536-59. PMID: 20525905
  8. Auriemma RS, Pirchio R, Pivonello C, et al. Approach to the Patient With Prolactinoma. J Clin Endocrinol Metab. 2023;108:2400-2423. PMID: 36974474
  9. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273-88. PMID: 21296991
  10. Diver MJ, Imtiaz KE, Ahmad AM, et al. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol (Oxf). 2003;58:710-7. PMID: 12780747
  11. Salonia A, Capogrosso P, Boeri L, et al. European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2025 Update on Male Hypogonadism, Erectile Dysfunction, Premature Ejaculation, and Peyronie’s Disease. Eur Urol. 2025;88:76-102. PMID: 40340108

Start with a lab panel

Get a clinical review of your results and health history, with an explanation of the decision and next steps in your patient chat. If you are eligible and want treatment, choose a plan and save a card to book a video visit at no extra visit fee. Treatment billing starts only if prescribed.

Order your lab panel

Prefer short video breakdowns? Follow @veedma.men on TikTok for quick, study-backed men's hormone explainers.

Vladimir Kotlov, MD

Vladimir Kotlov, MD: Founder & CEO at Veedma

Vladimir Kotlov, MD is the founder of Veedma. A urologist by training, he led a urology department at a fertility and reproductive clinic where he managed a team of 30+ clinicians and improved IVF outcomes by 24%. He then moved to Silicon Valley and spent five years advising healthtech companies before founding Veedma to help men access evidence-based hormone optimization and fertility care.